The University of Southampton
University of Southampton Institutional Repository

Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis

Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive pulmonary disease leading to death within a few years of diagnosis despite medical therapy. On the basis of methodologies of the Cochrane collaboration, this overview discusses the evidence for IPF therapy. Good-quality studies on oral corticosteroids, the most common medical therapy in use for IPF, are lacking. A few small studies have been carried out on the efficacy of many non-steroid immunosuppressive agents, and the results have been generally disappointing. The most extensively studied medical therapy, gamma interferon, showed a significant effect in a small randomized study, but its efficacy was not confirmed in a larger randomized-controlled trial. The long-awaited good news for patients affected by this deadly disease, and for their physicians, could come in the near future from large randomized-controlled trials with gamma interferon or other immunomodulatory agents
1035-1044
Luppi, F.
4a386f93-c228-4b1a-bd52-fcccf9fcb880
Cerri, S.
a3dd7b6b-c165-4337-ba85-072c99ed8547
Beghè, B.
d1835725-7d84-409c-b618-1b14033848d0
Fabbri, L.M.
bcd21e7a-25ed-458d-8cbf-500e45b79a1f
Richeldi, L.
47177d9c-731a-49a1-9cc6-4ac8f6bbbf26
Luppi, F.
4a386f93-c228-4b1a-bd52-fcccf9fcb880
Cerri, S.
a3dd7b6b-c165-4337-ba85-072c99ed8547
Beghè, B.
d1835725-7d84-409c-b618-1b14033848d0
Fabbri, L.M.
bcd21e7a-25ed-458d-8cbf-500e45b79a1f
Richeldi, L.
47177d9c-731a-49a1-9cc6-4ac8f6bbbf26

Luppi, F., Cerri, S., Beghè, B., Fabbri, L.M. and Richeldi, L. (2004) Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis. Respiratory Medicine, 98 (11), 1035-1044. (doi:10.1016/j.rmed.2004.07.019). (PMID:15526803)

Record type: Article

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive pulmonary disease leading to death within a few years of diagnosis despite medical therapy. On the basis of methodologies of the Cochrane collaboration, this overview discusses the evidence for IPF therapy. Good-quality studies on oral corticosteroids, the most common medical therapy in use for IPF, are lacking. A few small studies have been carried out on the efficacy of many non-steroid immunosuppressive agents, and the results have been generally disappointing. The most extensively studied medical therapy, gamma interferon, showed a significant effect in a small randomized study, but its efficacy was not confirmed in a larger randomized-controlled trial. The long-awaited good news for patients affected by this deadly disease, and for their physicians, could come in the near future from large randomized-controlled trials with gamma interferon or other immunomodulatory agents

Full text not available from this repository.

More information

Published date: November 2004
Organisations: Clinical & Experimental Sciences

Identifiers

Local EPrints ID: 369061
URI: https://eprints.soton.ac.uk/id/eprint/369061
PURE UUID: 9d2213f8-1daa-4460-b08c-5becd5935656

Catalogue record

Date deposited: 09 Oct 2014 11:12
Last modified: 18 Jul 2017 01:40

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×